Trial Profile

Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Oct 2022 Results assessing short-term changes on quality of life and attention in schizophrenia patients treated with cariprazine, presented at the 35th Annual Congress of the European College of Neuropsychopharmacology.
30 Jun 2021 Results of post -hoc analysis from NCT00404573, NCT01104779, NCT00694707, NCT01104766, NCT01104792, NCT00839852, NCT01412060, EudraCT 2012-005485-36 assessing safety Profile of Cariprazine and Potential Relevance for Patient Adherence in Schizophrenia presented at the 15th World Congress of Biological Psychiatry
15 Sep 2020 Results of post hoc pooled analysis (NCT01104766, NCT01104779, NCT00694707) assessing efficacy of cariprazine in the early stage of schizophrenia presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com